Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia.
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Biotron's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BIT underperformed the Australian Biotechs industry which returned 51.7% over the past year.
Return vs Market: BIT exceeded the Australian Market which returned -19.2% over the past year.
Price Volatility Vs. Market
How volatile is Biotron's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StThe Biotron (ASX:BIT) Share Price Has Gained 178%, So Why Not Pay It Some Attention?
1 month ago | Simply Wall StCompanies Like Biotron (ASX:BIT) Can Afford To Invest In Growth
2 months ago | Simply Wall StCan We See Significant Insider Ownership On The Biotron Limited (ASX:BIT) Share Register?
Is Biotron undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BIT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BIT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIT is overvalued based on its PB Ratio (7.9x) compared to the AU Biotechs industry average (2.5x).
How is Biotron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Biotron's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Biotron competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Biotron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIT is currently unprofitable.
Growing Profit Margin: BIT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIT is unprofitable, but has reduced losses over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare BIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.3%).
Return on Equity
High ROE: BIT has a negative Return on Equity (-40.74%), as it is currently unprofitable.
How is Biotron's financial position?
Financial Position Analysis
Short Term Liabilities: BIT's short term assets (A$8.7M) exceed its short term liabilities (A$378.9K).
Long Term Liabilities: BIT's short term assets (A$8.7M) exceed its long term liabilities (A$33.0K).
Debt to Equity History and Analysis
Debt Level: BIT is debt free.
Reducing Debt: BIT has not had any debt for past 5 years.
Inventory Level: BIT has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if BIT's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BIT has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 10.6% each year.
What is Biotron's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BIT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Michelle Miller, BSc., MSc., PhD, GCertAppFin (Finsia) serves as Chief Executive Officer of Biotron Ltd. and has been its Managing Director since June 2002. Dr. Miller served as Investment Manager at S ...
CEO Compensation Analysis
Compensation vs Market: Michelle's total compensation ($USD211.08K) is about average for companies of similar size in the Australian market ($USD238.58K).
Compensation vs Earnings: Michelle's compensation has increased whilst the company is unprofitable.
|CEO, MD & Executive Director||no data||AU$351.26k||0.45% A$347.2k|
|Independent Non Executive Chairman||20.08yrs||AU$77.04k||1.33% A$1.0m|
|Independent & Non-Executive Director||8.08yrs||AU$41.09k||0.52% A$402.9k|
|Independent & Non-Executive Director||8.08yrs||AU$41.09k||0.093% A$72.0k|
|Independent & Non-Executive Director||1.5yrs||AU$28.71k||0.11% A$88.0k|
Experienced Board: BIT's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BIT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.8%.
Biotron Limited's company bio, employee growth, exchange listings and data sources
- Name: Biotron Limited
- Ticker: BIT
- Exchange: ASX
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$77.213m
- Shares outstanding: 701.93m
- Website: https://www.biotron.com.au
Number of Employees
- Biotron Limited
- 56 Delhi Road
- Suite 3.3
- North Ryde
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BITND||ASX (Australian Securities Exchange)||NPV DFD 30/12/19 (EX-OPTION)||AU||AUD||No data|
|BITR.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 2001|
|BIT||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jan 2001|
|BIT||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jan 2001|
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including Dengue, Zika, Influenza, Ebola, and SARs. Biotron Limited is based in North Ryde, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 10:33|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.